Clinical Trial

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

Study acronym: ADHERE+
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP. Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to explore less frequent dosing of efgartigimod PH20 SC.
Protocol Amendment History 25 amendments
This ClinicalTrials.gov record has been amended 25 times since 2020-02-20; most recent amendment 2025-06-25.
Status change: Recruiting → Active, Not Recruiting 2023-08-03
Status change: Not Yet Recruiting → Recruiting 2020-10-01
Trial Details
NCT Number NCT04280718
Lead Sponsor argenx
Conditions Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Enrollment 229 participants
Start Date 2020-09-18
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-29